Cargando…

Production and Enhanced Anti‐tumor Activity of Tumor Necrosis Factor in Mice Treated with Cyclophosphamide

We demonstrated recently that the production of tumor necrosis factor (TNF) is induced in normal mice and in the immunosuppressed nude mouse model by the administration of muramyl dipeptide (MDP) derivatives followed by endotoxin (lipopolysaccharide). In the present study, the ability of this treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noso, Yoshihiro, Becker, Jeanne, Riveau, Gilles, Audibert, Francoise, Chedid, Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1990
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918104/ https://www.ncbi.nlm.nih.gov/pubmed/2121696 http://dx.doi.org/10.1111/j.1349-7006.1990.tb02671.x

Ejemplares similares

He-Wei Granule enhances anti-tumor activity of cyclophosphamide by changing tumor microenvironment
por: Zhai, Jianxiu, et al.
Publicado: (2021)

Grain-Sized Moxibustion Heightens the AntiTumor Effect of Cyclophosphamide in Hepa1-6 Bearing Mice
por: Zhu, Tao, et al.
Publicado: (2022)

Ovarian protection in cyclophosphamide-treated mice by fennel
por: Hassanpour, Azam, et al.
Publicado: (2017)

Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice
por: Alyamkina, Ekaterina A, et al.
Publicado: (2009)

Contrasting effects of cyclophosphamide on anti‐CTL‐associated protein 4 blockade therapy in two mouse tumor models
por: Iida, Yuichi, et al.
Publicado: (2017)

Repair of local bone erosions by combined treatment with parathyroid hormone, osteoprotegerin and anti-tumor necrosis factor in tumor necrosis factor-transgenic mice
por: Redlich, K, et al.
Publicado: (2003)

In vivo Anti‐tumor Efficacy of Polyethylene Glycol‐modified Tumor Necrosis Factor‐α against Tumor Necrosis Factor‐resistant Tumors
por: Tsutsumi, Yasuo, et al.
Publicado: (1996)

Risk for multidrug-resistant tuberculosis in patients treated with anti-tumor necrosis factor agents
por: Park, Jinkyeong, et al.
Publicado: (2023)

Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice
Publicado: (1987)

Tumor Necrosis Factor Production and Colon Cancer
por: Ito, Hisashi, et al.
Publicado: (1996)

Risk factors for latent tuberculosis infection in RA patients treated with anti-tumor necrosis factor
por: Huang, Shiang-Fen, et al.
Publicado: (2012)

Spontaneous production of tumor necrosis factor alpha by Kupffer cells of MRL/lpr mice
Publicado: (1988)

The effect of capsaicin on circulating biomarkers, soluble tumor necrosis factor and soluble tumor necrosis factor-receptor-1 and -2 levels in vivo using lipopolysaccharide-treated mice
por: Ijiri, Yoshio, et al.
Publicado: (2014)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Golimumab: A Novel Anti-Tumor Necrosis Factor
por: Rossini, Maurizio, et al.
Publicado: (2013)

Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy
por: Han, Sun Ae, et al.
Publicado: (2016)

Glucocorticoid-mediated inhibition of endotoxin-induced intratumor tumor necrosis factor production and tumor hemorrhagic necrosis and regression
Publicado: (1989)

Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis
por: Atan, Denize, et al.
Publicado: (2013)

Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice
por: LIN, GUANGZHU, et al.
Publicado: (2013)

THE INDUCTION OF GRAFT VERSUS HOST DISEASE IN MICE TREATED WITH CYCLOPHOSPHAMIDE
por: Owens, Albert H., et al.
Publicado: (1968)

Follicle Loss and Apoptosis in Cyclophosphamide-Treated Mice: What’s the Matter?
por: Chen, Xiu-Ying, et al.
Publicado: (2016)

Phycobiliproteins Ameliorate Gonadal Toxicity in Male Mice Treated with Cyclophosphamide
por: Briseño-Bugarín, Jorge, et al.
Publicado: (2021)

Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy
por: Dogra, Mohit, et al.
Publicado: (2018)

RNPS1 inhibits excessive tumor necrosis factor/tumor necrosis factor receptor signaling to support hematopoiesis in mice
por: Zhong, Xue, et al.
Publicado: (2022)

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
por: Lee, Jung Hoon, et al.
Publicado: (2007)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Weight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
por: Alsulaim, Toka M, et al.
Publicado: (2022)

Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters
por: Koszałka, Patrycja, et al.
Publicado: (2007)

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()
por: Ribeiro, Lara Beatriz Prata, et al.
Publicado: (2015)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Protective effects of ethyl pyruvate on sperm quality in cyclophosphamide treated mice
por: Bakhtiary, Zahra, et al.
Publicado: (2015)

Anti-Tumor Effects of Queen Bee Acid (10-Hydroxy-2-Decenoic Acid) Alone and in Combination with Cyclophosphamide and Its Cellular Mechanisms against Ehrlich Solid Tumor in Mice
por: Albalawi, Aishah E., et al.
Publicado: (2021)

Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1
por: Chopra, Martin, et al.
Publicado: (2013)

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
por: Kobie, James J, et al.
Publicado: (2011)

Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
por: Koo, Bon San, et al.
Publicado: (2015)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
por: Wu, Junjie, et al.
Publicado: (2016)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

Boosting In-Vivo Anti-Tumor Immunity with an Oral Microparticulate Breast Cancer Vaccine and Low-Dose Cyclophosphamide
por: Mulla, Nihal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b1sve2efmco3d78t4m2gk910hv